Geriatric Screening using the sG8 scale
OtherGeriatric screening using the sG8 scale
NCT Number: NCT06939764
This study is a multicenter, prospective, observational study. The study included patients aged 65 and older with solid tumors requiring systemic anti-tumor therapy. All patients underwent screening using the sG8 scale before the start of treatment, followed by routine treatment based on a plan developed through clinician decision-making. The study did not intervene in any way with the patients' diagnosis and treatment, and relevant clinical data during the treatment process were recorded accurately for follow-up patients. Study data were obtained from the electronic medical record databases and hospital information systems of multiple centers, including Sichuan Cancer Hospital. Patient clinicopathological features, pathological diagnoses, clinical stages, previous treatment histories, as well as anti-tumor treatment regimens after patient enrollment, drug dosages per cycle, treatment start times, incidence and grades of adverse events (AEs), and tumor response were extracted and collected from the medical records. All data were entered, managed, quality-controlled, exported, and analyzed through a real-world data management platform (RWDMP).
Trial opening soon.
Get Notified65 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Geriatric screening using the sG8 scale
Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months
The incidence of unplanned treatment delays and treatment interruptions
Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months
Number and percentage of patents with treatment-related adverse events assessed by CTCAE v5.0.
Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months
the sum percentage of participants with CR and PR assessed by RECIST v1.1 criteria every 8-12 weeks.
Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months.
Systemic Progression-Free Survival assessed by the investigators using RECIST V1.1.
Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of death or the end of study, whichever came first, assessed up to 12 months
Overall survival
Sichuan Cancer Hospital and Research Institute
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07510841
Solid Cancers
View Trial DetailsNCT07192315
Solid Cancers, Solid Tumor Malignancies
Marseille, France
View Trial DetailsNCT07427186
Solid Cancers
Toulouse, France
View Trial DetailsNCT07030478
Solid Cancers, Solid Tumours
View Trial Details